GO
Loading...

Enter multiple symbols separated by commas

Mortgage Applications Fell Last Week as Interest Rates Rose

U.S. mortgage applications declined last week, dragged down by sinking demand for home refinancing with long-term interest rates at their highest level since October, an industry group said on Wednesday.

The Mortgage Bankers Association's mortgage application index slipped 1.7 percent to a seasonally adjusted 625.3 in the week ended June 1.

A rise in applications to buy homes was overshadowed by the drop in refinancing applications.

The MBA's seasonally adjusted purchase index rose 1.5 percent to 433.6, but the refinancing gauge fell 6.1 percent to 1,757.1 in the June 1 week. The refinancing measure has not been lower since 1,640.4 at the end of last year.

Borrowing costs on 30-year fixed-rate mortgages, excluding fees, rose 0.03 percentage point to average 6.35 percent, its peak since 6.36 percent was reached in the Oct. 20 week.

Refinancings represented 38 percent of total mortgage applications, down from 39.7 percent the prior week and the lowest share since July.

On a four-week moving average, which smooths out volatility, all three of the MBA's seasonally adjusted indexes have fallen.

The mortgage applications index, also called the market index, is down 2.1 percent; the purchase index is off 0.3 percent and refinance index is down 4.3 percent.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • WiFi via drones

    Facebook wants to keep growing and has designed a drone that will provide Internet service in remote areas. CNBC's Julia Boorstin reports.

  • SoulCycle files for IPO

    CNBC's Dominic Chu reports the banks listed for underwriters for the SoulCycle IPO.

  • Street Talk: ORCL, SCTY, WDC, SFLY & RLYP

    "Power Lunch" hosts Melissa Lee and Brian Sullivan look at 5 stocks with analyst recommendations, including biotech Relypsa.